Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FGF8 isoform b expression in human prostate cancer.

V J Gnanapragasam1, M C Robinson, C Marsh

  • 1Prostate Research Group, School of Surgical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. V.J.Gnanapragasm@ncl.ac.uk

British Journal of Cancer
|June 5, 2003
PubMed
Summary

Fibroblast growth factor 8b (FGF8b) expression increases with prostate cancer stage and grade. Immunodetection of FGF8b shows potential as a prognostic marker for prostate cancer progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

British journal of cancer·2024
Same author

Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers.

British journal of cancer·2021
Same author

Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.

Cancer causes & control : CCC·2021
Same author

Atrial fibrillation and non-ischaemic cardiomyopathy in the peripartum period.

Anaesthesia reports·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation.

BMC medicine·2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • Fibroblast growth factor 8 (FGF8) mRNA overexpression is noted in prostate cancer.
  • The FGF8b isoform is implicated as a key player in prostate cancer development.

Purpose of the Study:

  • To investigate the prognostic value of fibroblast growth factor 8b (FGF8b) immunodetection in archival prostate cancer specimens.
  • To correlate FGF8b expression with clinical parameters, including cancer stage and histological grade.

Main Methods:

  • Immunohistochemistry was used to detect FGF8b expression in prostate cancer tissues from transurethral resections and radical prostatectomies.
  • Fluorescent in situ hybridization was employed to assess FGF8 gene copy number.

Main Results:

Related Experiment Videos

  • FGF8b was not detected in benign prostate tissues but showed localized expression in malignant epithelium.
  • FGF8b expression significantly correlated with advanced tumor stage (T3-T4) and higher Gleason scores (grade 8-10).
  • FGF8 gene copy number was similar in benign and malignant prostate cells, suggesting overexpression is not due to gene amplification.

Conclusions:

  • FGF8b immunoreactivity is significantly associated with adverse prognostic factors in prostate cancer.
  • FGF8b shows promise as a potential prognostic biomarker for prostate cancer.
  • Further multicenter studies are warranted to validate FGF8b as a prognostic marker.